Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence

The aim was to examine rifaximin plus lactulose efficacy in patients with cirrhosis at a risk of developing overt HE who were stratified by important baseline characteristics such as comorbid ascites or diabetes.